Literature DB >> 23253768

Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

E Jennifer Edelman1, David A Fiellin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23253768      PMCID： PMC3645931          DOI： 10.1016/j.amepre.2012.09.035

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN： 0749-3797            Impact factor:   5.043


× No keyword cloud information.
  58 in total

Review 1.  Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Authors:  Gavin M Myers; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2011-02       Impact factor: 5.078

2.  A US policy perspective on oral preexposure prophylaxis for HIV.

Authors:  Arleen A Leibowitz; Karen Byrnes Parker; Mary Jane Rotheram-Borus
Journal:  Am J Public Health       Date:  2011-04-14       Impact factor: 9.308

3.  Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates.

Authors:  William C Becker; Daniel G Tobin; David A Fiellin
Journal:  Arch Intern Med       Date:  2011-06-13

4.  Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Authors:  E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

5.  Rural residence is associated with delayed care entry and increased mortality among veterans with human immunodeficiency virus infection.

Authors:  Michael Ohl; Janet Tate; Mona Duggal; Melissa Skanderson; Matthew Scotch; Peter Kaboli; Mary Vaughan-Sarrazin; Amy Justice
Journal:  Med Care       Date:  2010-12       Impact factor: 2.983

6.  HIV/AIDS services in private substance abuse treatment programs.

Authors:  Amanda J Abraham; Lauren A O'Brien; Brian E Bride; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2010-12-08       Impact factor: 4.492

7.  Mechanisms of prescription drug diversion among drug-involved club- and street-based populations.

Authors:  James A Inciardi; Hilary L Surratt; Steven P Kurtz; Theodore J Cicero
Journal:  Pain Med       Date:  2007-03       Impact factor: 3.750

8.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

10.  Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions.

Authors:  Steffanie A Strathdee; Jamila K Stockman
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071
View more
  4 in total

1.  A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users.

Authors:  Dawn K Smith; Yi Pan; Charles E Rose; Sherri L Pals; Shruti H Mehta; Gregory D Kirk; Jeffrey H Herbst
Journal:  J Addict Med       Date:  2015 May-Jun       Impact factor: 3.702

2.  HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study.

Authors:  Douglas Krakower; Norma Ware; Jennifer A Mitty; Kevin Maloney; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2014-09

3.  Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers.

Authors:  E Jennifer Edelman; Brent A Moore; Sarah K Calabrese; Gail Berkenblit; Chinazo O Cunningham; Onyema Ogbuagu; Viraj V Patel; Karran A Phillips; Jeanette M Tetrault; Minesh Shah; Oni Blackstock
Journal:  Prev Med Rep       Date:  2019-10-21

4.  Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-06-14       Impact factor: 17.586
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.